Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020

NICE STABMJ Open

Apr 8

Written by Matthijs Versteegh

Matthijs Versteegh

Correcting for discounting and loss aversion in composite time trade-off

The Net Benefit of Personalized Medicine: a Systematic Literature Review and Regression Analysis